Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KALA
CUSIPN/A
Phone781-996-5252
Debt
Debt-to-Equity Ratio0.25
Current Ratio20.40
Quick Ratio20.40
Price-To-Earnings
Trailing P/E Ratio-2.17
Forward P/E Ratio-6.43
P/E GrowthN/A
Sales & Book Value
Annual Sales$40,000.00
Price / Sales7,779.38
Cash FlowN/A
Price / CashN/A
Book Value$3.66 per share
Price / Book3.46
Profitability
EPS (Most Recent Fiscal Year)($5.84)
Net Income$-42,210,000.00
Net MarginsN/A
Return on Equity-108.42%
Return on Assets-46.86%
Miscellaneous
Employees37
Outstanding Shares24,560,000
Market Cap$311.20
Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions
What is Kala Pharmaceuticals' stock symbol?
Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."
How were Kala Pharmaceuticals' earnings last quarter?
Kala Pharmaceuticals Inc (NASDAQ:KALA) posted its quarterly earnings data on Thursday, May, 10th. The company reported ($0.46) EPS for the quarter, topping the Zacks' consensus estimate of ($0.46) by $0.00. View Kala Pharmaceuticals' Earnings History.
What price target have analysts set for KALA?
5 brokerages have issued 12-month price targets for Kala Pharmaceuticals' stock. Their forecasts range from $19.00 to $47.00. On average, they expect Kala Pharmaceuticals' share price to reach $36.00 in the next twelve months. This suggests a possible upside of 184.1% from the stock's current price. View Analyst Ratings for Kala Pharmaceuticals.
What is the consensus analysts' recommendation for Kala Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Kala Pharmaceuticals' key competitors?
Some companies that are related to Kala Pharmaceuticals include Endocyte (ECYT), Zai Lab (ZLAB), Eagle Pharmaceuticals (EGRX), Athenex (ATNX), Tricida (TCDA), Retrophin (RTRX), Esperion Therapeutics (ESPR), Intra-Cellular Therapies (ITCI), Reata Pharmaceuticals (RETA), Revance Therapeutics (RVNC), Wave Life Sciences (WVE), Apellis Pharmaceuticals (APLS), TG Therapeutics Inc common stock (TGTX), OptiNose (OPTN) and Vanda Pharmaceuticals (VNDA).
Who are Kala Pharmaceuticals' key executives?
Kala Pharmaceuticals' management team includes the folowing people:
- Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 52)
- Mr. Todd Bazemore, Chief Operating Officer (Age 48)
- Dr. Kim Brazzell, Chief Medical Officer (Age 65)
- Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
- Ms. Mary Reumuth CPA, CFO & Treasurer (Age 43)
When did Kala Pharmaceuticals IPO?
(KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.
Has Kala Pharmaceuticals been receiving favorable news coverage?
Press coverage about KALA stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Kala Pharmaceuticals earned a media sentiment score of 0.07 on Accern's scale. They also gave news coverage about the company an impact score of 47.53 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Kala Pharmaceuticals?
Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kala Pharmaceuticals' stock price today?
One share of KALA stock can currently be purchased for approximately $12.67.
How big of a company is Kala Pharmaceuticals?
Kala Pharmaceuticals has a market capitalization of $311.20 million and generates $40,000.00 in revenue each year. The company earns $-42,210,000.00 in net income (profit) each year or ($5.84) on an earnings per share basis. Kala Pharmaceuticals employs 37 workers across the globe.
How can I contact Kala Pharmaceuticals?
Kala Pharmaceuticals' mailing address is 100 BEAVER STREET SUITE 201, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]
MarketBeat Community Rating for Kala Pharmaceuticals (NASDAQ KALA)
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
